Regional deep hyperthermia for salvage treatment of children and adolescents with refractory or recurrent non-testicular malignant germ-cell tumours: An open-label, non-randomised, single-institution, phase 2 study

The Lancet Oncology

Volumn 14, Issue 9, 2013, Pages 843-852

  Wessalowski, Rüdiger ^a   Schneider, Dominik T ^b   Mils, Oliver ^a   Friemann, Verena ^a   Kyrillopoulou, Olga ^a   Schaper, Jörg ^a   Matuschek, Christiane ^a   Rothe, Karin ^c   Leuschner, Ivo ^d   Willers, Reinhart ^a   Schönberger, Stefan ^e   Göbel, Ulrich ^a   Calaminus, Gabriele ^f  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b Municipal Hospital   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d UNIVERSITY OF KIEL   (Germany)

^e UNIVERSITY HOSPITAL BONN   (Germany)

^f UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; IFOSFAMIDE;

ADOLESCENT; ARTICLE; BLOOD TOXICITY; BRAIN DISEASE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURGERY; CANCER SURVIVAL; CHILD; CHORIOCARCINOMA; CLINICAL ARTICLE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSGERMINOMA; EMBRYONAL CARCINOMA; EVENT FREE SURVIVAL; FANCONI RENOTUBULAR SYNDROME; FEMALE; FOLLOW UP; GERM CELL TUMOR; HEARING IMPAIRMENT; HISTOPATHOLOGY; HUMAN; HYPERTHERMIC THERAPY; IATROGENIC DISEASE; INFECTION; MALE; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PANCREATITIS; PHASE 2 CLINICAL TRIAL; PRACTICE GUIDELINE; PRESCHOOL CHILD; PRIORITY JOURNAL; RECURRENT CANCER; SALVAGE THERAPY; SCHOOL CHILD; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUBULAR DYSFUNCTION;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; CISPLATIN; COMBINED MODALITY THERAPY; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTHERMIA, INDUCED; IFOSFAMIDE; INFANT; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASMS, GERM CELL AND EMBRYONAL; PROGNOSIS; PROSPECTIVE STUDIES; SALVAGE THERAPY; SURVIVAL RATE; YOUNG ADULT;

EID: 84880790164     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(13)70271-7     Document Type: Article

References (54)

1. Poynter JN, Amatruda JF, Ross JA Trends in incidence and survival of pediatric and adolescent patients with germ cell tumors in the United States, 1975 to 2006. Cancer 2010, 116:4882-4891.
2. Mann JR, Pearson D, Barrett A, et al. Results of the United Kingdom Children's Cancer Study Group's malignant germ cell tumor studies. Cancer 1989, 63:1657-1667.
3. Marina N, Fontanesi J, Kun L, et al. Treatment of childhood germ cell tumors. Review of the St Jude experience from 1979 to 1988. Cancer 1992, 70:2568-2575.
4. Bosl GJ, Motzer RJ Testicular germ-cell cancer. N Engl J Med 1997, 337:242-253.
5. Gobel U, Schneider DT, Calaminus G, et al. Germ-cell tumors in childhood and adolescence. Ann Oncol 2000, 11:263-271. GPOH MAKEI and the MAHO study groups.
6. Einhorn LH Testicular cancer as a model for a curable neoplasm: the Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 1981, 41:3275-3280.
7. Williams SD, Birch R, Einhorn LH, et al. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 1987, 316:1435-1440.
8. Pont J, Albrecht W, Postner G, et al. Adjuvant chemotherapy for high-risk clinical stage I nonseminomatous testicular germ cell cancer: long-term results of a prospective trial. J Clin Oncol 1996, 14:441-448.
9. Farhat F, Culine S, Theodore C, et al. Cisplatin and ifosfamide with either vinblastine or etoposide as salvage therapy for refractory or relapsing germ cell tumor patients: the Institut Gustave Roussy experience. Cancer 1996, 77:1193-1197.
10. Horwich A, Sleijfer DT, Fossa SD, et al. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. J Clin Oncol 1997, 15:1844-1852.
11. Calaminus G, Schneider DT, Bokkerink JP, et al. Prognostic value of tumor size, metastases, extension into bone, and increased tumor marker in children with malignant sacrococcygeal germ cell tumors: a prospective evaluation of 71 patients treated in the German cooperative protocols Maligne Keimzelltumoren (MAKEI) 83/86 and MAKEI 89. J Clin Oncol 2003, 21:781-786.
12. Cushing B, Giller R, Cullen JW, et al. Randomized comparison of combination chemotherapy with etoposide, bleomycin, and either high-dose or standard-dose cisplatin in children and adolescents with high-risk malignant germ cell tumors: a pediatric intergroup study-Pediatric Oncology Group 9049 and Children's Cancer Group 8882. J Clin Oncol 2004, 22:2691-2700.
13. Marina N, London WB, Frazier AL, et al. Prognostic factors in children with extragonadal malignant germ cell tumors: a pediatric intergroup study. J Clin Oncol 2006, 24:2544-2548.
14. Frazier AL, Rumcheva P, Olson T, et al. Application of the adult international germ cell classification system to pediatric malignant non-seminomatous germ cell tumors: a report from the Children's Oncology Group. Pediatr Blood Cancer 2008, 50:746-751.
15. Bernbeck B, Schneider DT, Bernbeck B, et al. Germ cell tumors of the head and neck: report from the MAKEI Study Group. Pediatr Blood Cancer 2009, 52:223-226.
16. Gobel U, Schneider DT, Teske C, et al. Brain metastases in children and adolescents with extracranial germ cell tumor- data of the MAHO/MAKEI-registry. Klin Padiatr 2010, 222:140-144.
17. Lack EE, Travis WD, Welch KJ Retroperitoneal germ cell tumors in childhood. A clinical and pathologic study of 11 cases. Cancer 1985, 56:602-608.
18. Wessalowski R, Kruck H, Pape H, et al. Hyperthermia for the treatment of patients with malignant germ cell tumors: a phase I/II study in ten children and adolescents with recurrent or refractory tumors. Cancer 1998, 82:793-800.
19. Schneider DT, Wessalowski R, Calaminus G, et al. Treatment of recurrent malignant sacrococcygeal germ cell tumors: analysis of 22 patients registered in the German protocols MAKEI 83/86, 89, and 96. J Clin Oncol 2001, 19:1951-1960.
20. Stehlin JS Hyperthermic perfusion with chemotherapy for cancers of the extremities. Surg Gynecol Obstet 1969, 129:305-308.
21. Eggermont AM, ten Hagen TL Tumor necrosis factor-based isolated limb perfusion for soft tissue sarcoma and melanoma: ten years of successful antivascular therapy. Curr Oncol Rep 2003, 5:79-80.
22. Sapozink MD, Gibbs FA, Egger MJ, et al. Regional hyperthermia for clinically advanced deep-seated pelvic malignancy. Am J Clin Oncol 1986, 9:162-169.
23. van der Zee J, Gonzalez Gonzalez D, van Rhoon GC, et al. Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: a prospective, randomised, multicentre trial. Lancet 2000, 355:1119-1125. for the Dutch Deep Hyperthermia Group.
24. Issels RD, Lindner LH, Verweij J, et al. Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. Lancet Oncol 2010, 11:561-570.
25. Russell WO, Cohen J, Enzinger F, et al. A clinical and pathological staging system for soft tissue sarcomas. Cancer 1977, 40:1562-1570.
26. Kottmeier HL Classification and staging of malignant tumours in the female pelvis. Acta Obstet Gynecol Scand 1971, 50:1-7.
27. Oleson JR, Dewhirst MW, Harrelson JM, et al. Tumor temperature distributions predict hyperthermia effect. Int J Radiat Oncol Biol Phys 1989, 16:559-570.
28. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981, 47:207-214.
29. Göbel U, Schneider DT, Calaminus G, et al. Multimodal treatment of malignant sacrococcygeal germ cell tumors: a prospective analysis of 66 patients of the German Cooperative Protocols MAKEI 83/86 and 89. J Clin Oncol 2001, 19:1943-1950.
30. Mann JR, Raafat F, Robinson K, et al. The United Kingdom Children's Cancer Study Group's second germ cell tumor study: carboplatin, etoposide, and bleomycin are effective treatment for children with malignant extracranial germ cell tumors, with acceptable toxicity. J Clin Oncol 2000, 18:3809-3818.
31. De Giorgi U, Rosti G, Slavin S, et al. Salvage high-dose chemotherapy for children with extragonadal germ-cell tumours. Br J Cancer 2005, 93:412-417.
32. Ablin AR, Krailo MD, Ramsay NK, et al. Results of treatment of malignant germ cell tumors in 93 children: a report from the Childrens Cancer Study Group. J Clin Oncol 1991, 9:1782-1792.
33. Rescorla F, Billmire D, Stolar C, et al. The effect of cisplatin dose and surgical resection in children with malignant germ cell tumors at the sacrococcygeal region: a pediatric intergroup trial (POG 9049/CCG 8882). J Pediatr Surg 2001, 36:12-17.
34. Billmire D, Vinocur C, Rescorla F, et al. Malignant retroperitoneal and abdominal germ cell tumors: an intergroup study. J Pediatr Surg 2003, 38:315-318.
35. Baranzelli MC, Kramar A, Bouffet E, et al. Prognostic factors in children with localized malignant nonseminomatous germ cell tumors. J Clin Oncol 1999, 17:1212.
36. Einhorn LH, Williams SD, Chamness A, et al. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med 2007, 357:340-348.
37. Lorch A, Bascoul-Mollevi C, Kramar A, et al. Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database. J Clin Oncol 2011, 29:2178-2184.
38. Rick O, Bokemeyer C, Weinknecht S, et al. Residual tumor resection after high-dose chemotherapy in patients with relapsed or refractory germ cell cancer. J Clin Oncol 2004, 22:3713-3719.
39. Gobel U, Calaminus G, Schneider DT, et al. Management of germ cell tumors in children: approaches to cure. Onkologie 2002, 25:14-22.
40. Hahn GM Potential for therapy of drugs and hyperthermia. Cancer Res 1979, 39:2264-2268.
41. Jones EL, Samulski TV, Dewhirst MW, et al. A pilot Phase II trial of concurrent radiotherapy, chemotherapy, and hyperthermia for locally advanced cervical carcinoma. Cancer 2003, 98:277-282.
42. Franckena M, De Wit R, Ansink AC, et al. Weekly systemic cisplatin plus locoregional hyperthermia: an effective treatment for patients with recurrent cervical carcinoma in a previously irradiated area. Int J Hyperthermia 2007, 23:443-450.
43. Alberts DS, Peng YM, Chen HS, et al. Therapeutic synergism of hyperthermia-cis-platinum in a mouse tumor model. J Natl Cancer Inst 1980, 65:455-461.
44. Meyn RE, Corry PM, Fletcher SE, et al. Thermal enhancement of DNA damage in mammalian cells treated with cis-diamminedichloroplatinum(II). Cancer Res 1980, 40:1136-1139.
45. Krawczyk PM, Eppink B, Essers J, et al. Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibition. Proc Natl Acad Sci USA 2011, 108:9851-9856.
46. Muenyi CS, Pinhas AR, Fan TW, et al. Sodium arsenite {+/-} hyperthermia sensitizes p53 expressing human ovarian cancer cells to cisplatin by modulating platinum DNA damage responses. Toxicol Sci 2012, 127:139-149.
47. Raaphorst GP, Chabot P, Doja S, et al. Effect of hyperthermia on cisplatin sensitivity in human glioma and ovarian carcinoma cell lines resistant and sensitive to cisplatin treatment. Int J Hyperthermia 1996, 12:211-222.
48. Hettinga JV, Konings AW, Kampinga HH Reduction of cellular cisplatin resistance by hyperthermia-a review. Int J Hyperthermia 1997, 13:439-457.
49. Debes A, Willers R, Gobel U, et al. Role of heat treatment in childhood cancers: distinct resistance profiles of solid tumor cell lines towards combined thermochemotherapy. Pediatr Blood Cancer 2005, 45:663-669.
50. Wondergem J, Bulger RE, Strebel FR, et al. Effect of cis-diamminedichloroplatinum(II) combined with whole body hyperthermia on renal injury. Cancer Res 1988, 48:440-446.
51. Gobel U, Calaminus G, Teske C, et al. BEP/VIP in children and adolescents with malignant non-testicular germ cell tumors. A comparison of the results of treatment of therapy studies MAKEI 83/86 and 89P/89. Klin Padiatr 1993, 205:231-240. (in German).
52. Feldmann HJ, Molls M, Heinemann HG, et al. Thermoradiotherapy in locally advanced deep seated tumours-thermal parameters and treatment results. Radiother Oncol 1993, 26:38-44.
53. Bruggmoser G, Bauchowitz S, Canters R, et al. Quality assurance for clinical studies in regional deep hyperthermia. Strahlenther Onkol 2011, 187:605-610.
54. Jones EL, Oleson JR, Prosnitz LR, et al. Randomized trial of hyperthermia and radiation for superficial tumors. J Clin Oncol 2005, 23:3079-3085.